Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective
Year: 2015
Type: review
Abstract: Herpes zoster (HZ) is primarily a disease of nerve tissue but the acute and longer-term manifestations require multidisciplinary knowledge and involvement in their management. Complications may be dermatological (e.g. secondary bacterial infection), neurological (e.g. long-term pain, segmental paresis, stroke), ophthalmological (e.g. keratitis, iridocyclitis, secondary glaucoma) or visceral (e.g. pneumonia, hepatitis). The age-related increased incidence of HZ and its complications is thought to be a result of the decline in cell-mediated immunity (immunosenescence), higher incidence of comorbidities with age and social-environmental changes. Individuals who are immunocompromised as a result of disease or therapy are also at increased risk, independent of age. HZ and its complications (particularly postherpetic neuralgia) create a significant burden for the patient, carers, healthcare systems and employers. Prevention and treatment of HZ complications remain a therapeutic challenge despite recent advances. This is an overview of the multidisciplinary implications and management of HZ in which the potential contribution of vaccination to reducing the incidence HZ and its complications are also discussed.
Source: Therapeutic Advances in Vaccines
Institutions: University of Bristol, Madrid Health Service, Martini Ziekenhuis, University of Rome Tor Vergata, Centre Hospitalier Annecy Genevois, University of Lisbon, Université Paris-Sud, Centre National de la Recherche Scientifique, Assistance Publique – Hôpitaux de Paris, Institut de Biologie Intégrative de la Cellule, Bicêtre Hospital, University Hospital of Geneva, Ospedale Papa Giovanni XXIII, Universitat de Barcelona, Klinikum Ernst von Bergmann
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: herpes zoster, postherpetic neuralgia, herpes zoster complications, immunosenescence, immunocompromised patients, comorbidities, herpes zoster vaccination, economic burden, health care costs, ocular complications, neurological complications, secondary bacterial infection, multidisciplinary management
Open Access status: bronze
Funders: Public Health Agency, Sanofi Pasteur
OpenAlex ID: W2180178398
